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Abstract
Background: Multimorbidity is a growing concern for healthcare systems, with many countries experiencing
demographic transition to older population profiles. Chronic kidney disease (CKD) is common but often considered
in isolation. The extent and prognostic significance of its comorbidities is not well understood. This study aimed to
assess the extent and prognostic significance of 11 comorbidities in people with CKD stage 3.
Methods: A prospective cohort of 1741 people with CKD stage 3 was recruited from primary care between August
2008 and March 2010. Participants underwent medical history, clinical assessment, blood and urine sampling.
Comorbidity was defined by self-reported doctor-diagnosed condition, disease-specific medication or blood results
(hemoglobin), and treatment burden as number of ongoing medications. Logistic regression was used to identify
associations with greater treatment burden (taking >5 medications) and greater multimorbidity (3 or more
comorbidities). Kaplan Meier plots and multivariate Cox proportional hazards models were used to investigate
associations between multimorbidity and all-cause mortality.
Results: One thousand seven hundred forty-one people were recruited, mean age 72.9 +/−9 years. Mean baseline
eGFR was 52 ml/min/1.73 m2. Only 78/1741 (4 %) had no comorbidities, 453/1741 (26 %) had one, 508/1741 (29 %)
had two and 702/1741 (40 %) had >2. Hypertension was common (88 %), 30 % had ‘painful condition’, 24 %
anemia, 23 %, ischaemic heart disease, 17 % diabetes and 12 % thyroid disorders. Median medication use was 5
medications (interquartile range 3–8) and increased with degree of comorbidity. Greater treatment burden and
multimorbidity were independently associated with age, smoking, increasing body mass index and decreasing
eGFR. Treatment burden was also independently associated with lower education status. After median 3.6 years
follow-up, 175/1741 (10 %) died. Greater multimorbidity was independently associated with mortality (hazard ratio
2.81 (95 % confidence intervals 1.72–4.58), p < 0.001) for 3 or more comorbidities vs 0 or 1).
Conclusions: Isolated CKD was rare and multimorbidity the norm in this cohort of people with moderate CKD.
Increasing multimorbidity was associated with greater medication burden and poorer survival. CKD management
should include consideration of comorbidities.
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Background
Chronic kidney disease (CKD) is often viewed in isola-
tion and clinical guidelines for the condition commonly
focus on the consequences of impaired glomerular func-
tion and proteinuria [1, 2]. This approach neglects the
reality that the prevalence of CKD rises steeply with age
and it is therefore likely to occur in the setting of mul-
tiple comorbid conditions including hypertension, dia-
betes and cardiovascular disease [3]. ‘Multimorbidity’ is
usually defined as having two or more chronic morbidities,
therefore people with CKD who have one or more comor-
bidity meet this definition [3]. Comorbidities are important
because they may impact on treatment burden, medica-
tions management, quality of life, and survival [4–6]. In
addition multiple comorbidity and associated polyphar-
macy have major implications for patients’ capacity to cope
with treatment as considered in a ‘burden of treatment
model’ [7, 8]. This describes the actions that patients are
required to undertake to successfully manage their condi-
tion as ‘work’ (both self-management and in interaction
with health services) and their ability to respond appropri-
ately as ‘capacity’ [7, 8]. As disease burden increases (due
to disease complexity, severity or number of conditions) so
does the work required of patients, and their capacity to
respond may suffer, leading to poor outcomes as shown in
other chronic conditions such as stroke [9].
Optimal clinical management of CKD would therefore
benefit from better understanding of the nature, extent
and prognostic implications of its common comorbidi-
ties in combination. This has been studied to some ex-
tent in dialysis populations and comorbidities have been
included in risk scores to aid clinical decision making in
transplant evaluation in the elderly, but less studied in
earlier CKD [10, 11]. In many countries, including the
UK, early CKD and its common comorbidities are prin-
cipally managed in primary care [12]. This study there-
fore aimed to describe the extent, distribution and
survival implications of eleven comorbidities, and the as-
sociated medication burden, in a cohort of people with
CKD stage 3 in a primary care setting.
Methods
Participants
Participants were recruited from 32 general practitioner
surgeries for the Renal Risk in Derby (RRID) study, a
prospective cohort study of CKD stage 3 in a primary
care setting. Detailed methods for the RRID study have
been published elsewhere [13]. Eligible participants were
18 years or over, met the Kidney Disease Outcomes
Quality Initiative (KDOQI) criteria for CKD stage 3
(current guidelines at the time of recruitment), able to
attend their GP surgery and to give informed consent.
People with previous transplant or terminal illness were
excluded. Screening and baseline visits were combined
due to the large proportion of elderly participants and lo-
gistical challenges of conducting study visits in multiple
primary care centers. First study visits occurred from
August 2008 to March 2010, questionnaire information
was checked, anthropomorphic measurements taken, urin-
alysis performed, and blood specimens taken. All partici-
pants provided written informed consent. The study was
approved by Nottingham Research Ethics Committee 1
and included on the National Institute for Health Research
Clinical Research Portfolio (NIHR Study ID:6632).
Definitions
The eleven comorbidities included in these analyses
were hypertension, diabetes, ischaemic heart disease,
heart failure, peripheral vascular disease, cerebrovascular
disease, chronic respiratory disorder, depression, chronic
painful condition, thyroid disorder and anaemia. These
comorbidities were chosen for pragmatic reasons includ-
ing ease of identification from patient report, medication
history, and laboratory data, and because they represent
a broad spectrum of chronic conditions prevalent among
older people.
Participants were asked to list chronic medications on
a questionnaire including details of any regular pain
medication taken. These were confirmed verbally at
study visits and further verified by examination of repeat
prescriptions where possible.
Blood pressure was measured after a minimum of five
minutes rest in the sitting position, using a validated
oscillometric device, recommended by the British Hyper-
tension Society (Digital Blood Pressure Monitor Model
UA-767, A & D Instruments Ltd, Abingdon, UK). The
same device was used for all readings. BP was calculated
as the mean of three readings that differed by <10 %.
Hypertension was defined as taking current antihyper-
tensive medication, or systolic BP >140 mmHg or dia-
stolic BP >90 mmHg at baseline. Diabetes was defined
by self-report of having a previous clinical diagnosis in
line with World Health Organisation criteria or being on
medication for diabetes [14]. Ischemic heart disease was
defined as participant-reported myocardial infarction or
coronary revascularisation procedure. Heart failure was
defined as patient reported clinical diagnosis. Peripheral
vascular disease was defined as peripheral arterial revas-
cularization or amputation. Cerebrovascular disease was
defined as participant-reported stroke or transient ische-
mic attack. Chronic respiratory disorder was defined by
chronic use of inhaled beta-2 adrenergic agonists (either
short or long acting) and / or inhaled steroid. The details
of all reported comorbidities were checked verbally with
participants at study vists. Depression was defined as on-
going use of a selective serotonin reuptake inhibitor or
serotonin–norepinephrine reuptake inhibitor. Thyroid
disorders were defined by taking thyroxine or carbimazole.
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Anemia was defined according to Kidney Disease
Improving Global Outcomes (KDIGO) guidelines as
haemoglobin <13.0 g/dl (<130 g/l) in males and <12.0 g/dl
(120 g/l) in females at baseline [1]. Painful condition was
defined as ongoing regular analgesia use.
Smoking status was categorized as never smoked, ex-
smoker, and current smoker. Socioeconomic status
(SES) was defined by two methods. First, using the Indi-
ces of Multiple Deprivation score (IMD); a small area
social deprivation score comprising a composite measure
of seven domains (income, employment, health and dis-
ability, education skills and training, barriers to housing
and other services, crime and living environment) [15].
Second, using self-reported education status; an import-
ant indicator of socioeconomic status in elderly popula-
tions [16]. Education status was categorized into three
groups (1: no formal qualifications, 2 : school or equiva-
lent qualifications, 3: degree or equivalent). Self-reported
ethnicity information was collected and, due to the small
number of non-white participants, categorized into
‘White’ and ‘Other’ for analysis. eGFR was calculated
using the Chronic Kidney Disease Epidemiology Collab-
oration (CKDEPI) equation [17]. Albuminuria was de-
fined as albumin/creatinine ratio (uACR) ≥3 mg/mmol
in at least two of the three urine specimens. uACR was
fitted as a continuous variable in regression analyses as
log of the mean of three uACR values. Body mass index
(BMI) was calculated from weight in kilograms divided
by height squared in meters [18].
Outcomes
Participants were registered with the Health and Social
Care Information Centre to obtain date and cause of
death. The observation period was from date of recruit-
ment until 24th February 2013. Cause of death was as
recorded on the death certificate. Causes of death were
independently reviewed by three investigators and classi-
fied as cardiovascular, cancer, infection or other. Classifi-
cation differences were resolved by discussion.
Statistical analyses
Descriptive statistics were used to summarise the fre-
quency and distribution of the numbers and types of co-
morbidities and the numbers of medications at baseline.
These were described in terms of having isolated CKD,
CKD plus one, two, or more than two comorbidities,
and taking less than five, more than five, or more than
ten medications. Chi square tests were used to compare
categorical variables.
Univariate and multivariable logistic regression models
were used to identify associations with greater treatment
burden (defined as taking more than five medications)
and greater multimorbidity (defined as more than two
comorbidities). Specific conditions were not included in
the treatment burden analysis as several conditions were
defined by medication status. A Kaplan Meier plot for
all-cause mortality and Cox proportional hazards models
were used to describe survival by degree of comorbidity.
Cox regression models were developed with multimor-
bidity fitted as a categorical variable (comparing people
with more than two vs. two comorbidities vs none or
one) with subsequent addition of sociodemographic
(age, sex, education status, IMD) and then lifestyle and
clinical variables (smoking, BMI, eGFR, uACR). The final
model included variables with a p value < 0.10 on univari-
ate analysis. Proportional hazards assumptions were
checked using Nelson–Aalen plots. Interactions between
age and smoking, sex and smoking and comorbidity and
smoking were checked because of the potential for these
factors to modify the mortality effect of smoking [19].
Results
A total of 1741 people were recruited to the RRID study.
The study population was predominantly white (>98 %)
and elderly. Mean age was 72.9 +/−9 and 67 % were over
70 years. Mean baseline eGFR was 52 ± 10 ml/min/
1.73 m2 (911 participants (52.3 %) were CKD stage 3a,
386 participants (22.2 %) were stage 3b). Isolated CKD
was uncommon; only 78/1741 (4 %) had no comorbidi-
ties in the list considered, 453/1741 (26 %) had at least
one comorbidity, 508/1741 (29 %) had two comorbidities
of the list considered and 702/1741 (40 %) had more
than two comorbidities. At baseline, having three or
more comorbidities was more common in men, older
people, people with CKD G3b, ex-smokers, and people
with greater socioeconomic deprivation, lower educa-
tional attainment, higher BMI, or any albuminuria
(Table 1). Hypertension was the commonest comorbidity
and painful condition the second (Table 2). The median
number of medications at baseline was five (interquartile
range 3–8); 1033/1741 (59 %) were taking five or more
medications and 198/1741 (11 %) ten or more and only
46 (3 %) were taking no medication. Greater comorbidity
burden was associated with taking higher numbers of
medications (p < 0.001 for trend, Table 1). On multivari-
able logistic regression, greater treatment burden (taking
more than five medications) and greater multimorbidity
(three or more comorbidities) were both independently
associated with increasing age, smoking, increasing BMI
and decreasing eGFR (Table 3). Greater treatment bur-
den was also independently associated with lower educa-
tion status (Table 3).
Overall mean follow-up time was 3.6 ± 0.8 years
(1317 ± 287 days). 175 participants (10 %) died during fol-
low up and 1537 (90 %) remained alive. Those who died
tended to be older, male, have fewer educational qualifica-
tions, have a history of smoking, and have CVD and/or
diabetes. The commonest cause of death was CVD (41 %)
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followed by cancer (29 %). People with two or more co-
morbidities experienced poorer survival (Fig. 1). On uni-
variate Cox regression analyses, male sex, age, history of
smoking, lower BMI, lower eGFR, albuminuria, and
greater number of comorbidities were associated with in-
creased risk of all-cause mortality (full data not shown).
After adjustment for socio-demographic variables, the re-
lationship between number of comorbidities and all-cause
mortality was attenuated (from 4.58 (95 % confidence in-
tervals (CI) 2.85–7.38) to 3.15 (95 % I 1.95–5.10, p <
0.001) for three or more compared to one or no comor-
bidities). Greater number of comorbidities, increasing age,
male sex, ex-smoking and lower eGFR remained signifi-
cantly associated with increased risk of all-cause mortality
in the final model (adjusting for age, sex, lifestyle and clin-
ical variables, Table 4). No interactions were identified.
Discussion
In this cohort study of predominantly older people with
mild to moderate CKD we found high levels of comor-
bidity and polypharmacy and demonstrated that in-
creased comorbidity was associated with reduced
survival. While our list of included comorbidities was
not exhaustive, our findings demonstrate that, even in a
cohort recruited in primary care, CKD rarely occurs in
isolation. Virtually all patients were ‘multimorbid’ ac-
cording to the usual definition of having two or more
chronic morbidities [3]. Our finding that only 4 % of
people with CKD stage 3 had no comorbidity is striking
and clinically important.
Strengths and limitations
This study had several strengths, including large numbers
of people with CKD, being conducted in a primary care
setting, ascertainment of a broad range of comorbidities
by interview rather than routine data, and prospective
follow-up. However, we recognise important limitations.
We did not have an age-matched control group without
CKD with whom to compare multimorbidity burden. It is
also likely that we under-identified some comorbidities by
use of patient self-report (such as heart failure) and
medication-definition; depression and respiratory disor-
ders, for example, were defined by medication only, thus
reducing their prevalence in our study. We were unable to
include certain important CKD comorbidities such as
cancer and liver disease because people with terminal
illness were excluded and, although participants were
asked about co-exisiting conditions, specific questions
about all forms of cancer were not included in the base-
line questionnaire. In addition, the prevalence of
patient-reported liver disease was considered too low to
meaningfully include in analyses and thought likely to
be under-ascertained by patient self-report as largely
asymptomatic (data not shown). The use of a
medication-driven definition will, to some extent, be a
reflection of the ‘work’ patients are required to do in
managing a condition, but defining conditions by medi-
cation meant that we were unable to include them as
variables in our logistic regression models. This re-
duced our ability to examine whether medication bur-
den had greatest association with specific conditions.
There is also no agreed method of defining morbidities.
We considered causative factors and potential CKD
complications if they affected quality life per se or
treatment burden through their management, and or
prognosis. Anaemia and hypertension were included for
these reasons. We did not include obesity as this is
largely asymptomatic, though we recognise that follow-
ing lifestyle advice maybe burdensome and symptoms
may develop as obesity increases. Including obesity as an
additional comorbidity would have increased overall bur-
den. These uncertainties would benefit from further dis-
cussion and consensus in people with CKD [20].
We were unable to consider frailty (which has been
shown to be associated with CKD) or cognitive impair-
ment both of which may influence patient capacity and
outcome, or other outcomes such as quality of life
(which might be more sensitive to some of our morbidities
than mortality), this will be assessed in later follow up
stages of this cohort [21–23]. Similarly, our assessment of
comorbidities does not account for disease severity. Con-
ditions causing pain, such as osteoarthritis, were not iden-
tified individually. Participants volunteered for this study,
so we may have selected a population with less comorbid-
ity and lower frailty. We also had no data on the burden
of health care (such as clinic visits) or medication adher-
ence. The combined effects of these limitations is that
even the high prevalence of comorbidities that we have re-
ported is likely to be an underestimate.
Table 2 Prevalence of individual comorbidities at baseline in
the RRID study
Comorbidity n Prevalence
Hypertension 1528 87.8 %
Painful condition 530 30.4 %
Anaemia 418 24.0 %
Ischaemic heart disease 398 22.9 %
Diabetes 294 16.9 %
Thyroid disorder 208 11.9 %
Cerebrovascular disease 200 11.5 %
Respiratory condition 181 10.4 %
Depression 94 5.4 %
Peripheral vascular disease 82 4.7 %
Heart failure 61 3.5 %
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Comparison with existing literature
The debate regarding the relevance of early or mild CKD
has often focussed on the hypothetical person with re-
duced GFR and no other medical problems but our data
show that this combination is only present in a very small
minority [24]. In the majority, CKD was associated with
other medical problems and 40 % had more than two co-
morbidities. Multiple studies have shown that the pres-
ence of CKD increases the risk of adverse outcomes
associated with a wide range of other diseases and, as we
have shown, greater comorbidity is associated with in-
creased all-cause mortality even in mild to moderate CKD
[25–28]. In a historical prospective cohort study of people
with CKD identified from electronic patient records, Gul-
lion et al. identified that, compared to age and sex
matched controls without CKD, people with CKD had
higher levels of comorbidity and higher risk of mortality
for the same degree of comorbidity [29]. Thus there is
mutual amplification of risks associated with CKD and co-
morbid conditions. Taken together these observations
imply that it is important to consider the implications of
CKD for the integrated care of patients with multimorbid-
ity. The presence of multiple comorbid conditions has im-
portant implications for medicines management [30]. We
identified very high prevalence of polypharmacy with 59 %
of people taking five or more medications and 11 % taking
ten or more. Furthermore, perhaps unsurprisingly, a
greater number of comorbidities was associated with a
greater number of medications. We showed that taking
more than five medications was independently associated
with older age and lower education status. Many com-
monly used medications require dose adjustments for re-
duced GFR and polypharmacy is associated with increased
risk of adverse drug interactions and risk of acute kidney
injury [31]. As the majority of patients with CKD are eld-
erly and more susceptible to adverse drug effects, our data
suggest that careful medicines management (including co-
ordination between pharmacists and community and hos-
pital physicians) should form an important part of the
care of people with CKD.
Burden of treatment is a relatively under-studied con-
sideration in CKD, the more common focus being bur-
den of illness [32–34]. The cumulative complexity of
developing new comorbidities and the balance of work
and capacity have implications for the success of self-
and shared-management efforts, increasingly recognised
in other chronic conditions such as stroke and heart fail-
ure [9, 35, 36]. The burden of comorbidities is usually
higher in groups with lower socioeconomic status and/
or lower educational attainment as we have shown in
this cohort [3]. Lower socioeconomic status is also
linked to lower health literacy - a key component of pa-
tients’ capacity [37]. An unexpected but important find-
ing of our study was the high prevalence of certain
conditions in this population, for example ‘painful condi-
tion’ and depression, though both were probably under-
estimated in our study due to reliance on medication for
their definition. Both may also adversely influence cap-
acity and are common in older people in general popula-
tion studies in the UK [38, 39]. Thus our data confirm
that mild CKD is associated with high disease burden,
high treatment burden and reduced capacity to cope
with the demands of treatment. These factors should be
considered when developing and agreeing care plans for
people with CKD.
Implications for research and practice
A patient-centred approach to managing patients with
multimorbidity (such as that recommended by the
American Geriatrics Society) is in line with evidence that
risks of fragmentation of care and medical error related
to multimorbidity can be ameliorated by a dedicated clin-
ician acting in an overseeing role [40–42]. Generalists in
integrated primary care teams are usually best placed to
offer this continuity of care and clinical oversight in mild
to moderate CKD though, as CKD advances, nephrolo-
gists commonly adopt this role. Improving care coordin-
ation has the potential to improve outcomes and reduce
health care costs for people with multimorbidity. This in-
cludes improving medicines management as discussed
above. Informed decision-making is challenging in multi-
morbidity and there is need to be judicious in adding to
patients’ treatment burden, particularly for treatments that
do not relieve symptoms but reduce future risk. This may
be particularly important in older patients with CKD,
whom we have shown have a high prevalence of comor-
bidities and reduced capacity.
We were unable to describe severity of the comorbid
conditions or quality of life in this study, which repre-
sent important considerations for future research. There
are also implications of the high prevalence of comor-
bidities to clinical trial design in people with CKD
(where people with comorbidities may be excluded from
trials). Further research should also investigate to what
Fig. 1 Kaplan Meier plot showing cumulative survival (all-cause
mortality) by comorbidity status. Footnote to Fig. 1: Please note that
the x axis does not cross the y axis at 0 %
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extent comorbidities may be caused or exacerbated by
CKD (e.g. anaemia).
Conclusions
In this cohort of people with moderate CKD, we identi-
fied that isolated CKD was rare and multimorbidity the
norm. Polypharmacy as a measure of treatment burden
was common, linked to degree of comorbidity and associ-
ated with older age and lower education status. Survival
was independently associated with greater number of co-
morbidities. Integrated care for people with CKD should
go beyond a focus on reduced GFR or albuminuria and in-
clude consideration of the burden of comorbidities (and
their treatments) balanced against patient capacity to cope
with further investigation and treatment.
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